What is Roseburia?

May 25, 2023 2 min read

What is Roseburia?

Roseburia is a genus of bacteria belonging to the family Lachnospiraceae, which is known for its beneficial effects on gut health. Here are some key points about Roseburia:

  • Roseburia is a Gram-positive, anaerobic, butyrate-producing bacteria that is commonly found in the human gut. It is one of the most abundant species of bacteria in the human colon, where it plays a crucial role in maintaining gut health.
  • Roseburia is known to have a positive impact on the immune system by producing short-chain fatty acids (SCFAs) such as butyrate, which serve as a source of energy for colon cells and are involved in regulating inflammation in the gut. Butyrate also has anti-inflammatory properties and is important for the maintenance of gut barrier function.
  • Studies have shown that a reduction in Roseburia abundance in the gut is associated with several inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis. In addition, a decrease in Roseburia levels has been observed in individuals with obesity and type 2 diabetes.
  • Roseburia is also important for the breakdown of complex carbohydrates, such as dietary fiber, which cannot be digested by the human host. The bacteria uses enzymes to break down these complex carbohydrates into simple sugars, which can then be used for energy production by the host. This process is important for maintaining a healthy gut microbiome.
  • Furthermore, Roseburia has been shown to produce metabolites that have potential therapeutic effects, such as bacteriocins, which are antimicrobial peptides that can help to prevent the growth of harmful bacteria in the gut.

References:

  1. Belenguer A, Duncan SH, Calder AG, Holtrop G, Louis P, Lobley GE, Flint HJ. Two routes of metabolic cross-feeding between Bifidobacterium adolescentis and butyrate-producing anaerobes from the human gut. Appl Environ Microbiol. 2006 Dec;72(12):3593-9. doi: 10.1128/AEM.72.5.3593-3599.2006. PMID: 16751530; PMCID: PMC1489366.
  2. Lopez-Siles M, Enrich-Capó N, Aldeguer X, Sabat-Mir M, Duncan SH, Garcia-Gil LJ, Martinez-Medina M. Alterations in the Abundance and Co-occurrence of Akkermansia muciniphila and Faecalibacterium prausnitzii in the Colonic Mucosa of Inflammatory Bowel Disease Subjects. Front Cell Infect Microbiol. 2018 Mar 13;8:281. doi: 10.3389/fcimb.2018.00281. PMID: 29594161; PMCID: PMC5853734.
  3. Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol. 2017 Jan;19(1):29-41. doi: 10.1111/1462-2920.13589. Epub 2016 Dec 20. PMID: 27813210.
  4. Vital M, Howe AC, Tiedje JM. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. MBio. 2014 Dec 9;5(6):e00889. doi: 10.1128/mBio.00889-14. PMID: 25491348; PMCID: PMC4278896.
  5. Rossi M, Amaretti A, Raimondi S. Folate Production by Probiotic Bacteria. Nutrients. 2011;3(1):118-134. doi:10.3390/nu3010118


Leave a comment


Also in GUT HEALTH KNOWLEDGE CENTER

Study Finds Individual Differences in the Response to Resistant Starch Consumption
Study Finds Individual Differences in the Response to Resistant Starch Consumption

August 25, 2024 7 min read

We all know we should eat more fiber but what if our gut doesn't react to fiber in the way we think it should? In this article, we delve into the results of a recent study that identifies the individual responses to resistant starch.
Read More
Human Milk Oligosaccharides Promote Better Gut Outcomes In Autistic Children Compared To Inulin, Study Finds
Human Milk Oligosaccharides Promote Better Gut Outcomes In Autistic Children Compared To Inulin, A 60-Child Clinical Trial

August 11, 2024 10 min read

Discover how HMOs may relieve or improve gastrointestinal symptoms in autistic children.
Read More
Even Low Doses (0.3 g/Day) of HMOs Have a Positive Impact on Adults and Children, Study Finds- Cover Image
Even Low Doses of HMOs Have a Positive Impact on Adults and Children, Study Finds

August 03, 2024 8 min read

Here, we explore the results of recent research investigating the potential effects of HMOs (2'-FL, LNnT, 3'-SL, 6'-SL) at daily doses of 0.3 - 5 g/day.
Read More